Nuclear Receptors in Nonalcoholic Fatty Liver Disease
Open accessThe DOI matches its Crossref record; 97 of the 97 references it cites were found in a registry or an index.
Abstract
Nuclear receptors comprise a superfamily of ligand-activated transcription factors that are involved in important aspects of hepatic physiology and pathophysiology. There are about 48 nuclear receptors in the human. These nuclear receptors are regulators of many hepatic processes including hepatic lipid and glucose metabolism, bile acid homeostasis, drug detoxification, inflammation, regeneration, fibrosis, and tumor formation. Some of these receptors are sensitive to the levels of molecules that control lipid metabolism including fatty acids, oxysterols, and lipophilic molecules. These receptors direct such molecules to the transcriptional networks and may play roles in the pathogenesis and treatment of nonalcoholic fatty liver disease. Understanding the mechanisms underlying the involvement of nuclear receptors in the pathogenesis of nonalcoholic fatty liver disease may offer targets for the development of new treatments for this liver disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
![Figure 1 (a) Schematic representation of a typical nuclear receptor. Nuclear receptors may be divided into five regions based on structural and functional similarities (denoted A, B, C, D, E, and F). Regions C and E contain the conserved DNA-binding domains (DBDs) and ligand-binding domains (LBDs) that are the signature of this superfamily. In addition, the constitutive transport element (CTE) is a dimerization region within the LBD and two transactivation domains (denoted AF-1 and AF-2/τc). A second dimerization domain (not shown) exists in the DBD and is required for heterodimerization of receptors on response elements. (b) NR function. Ligand binding to NRs triggers changes in their conformation leading to the dissociation of corepressors and the recruitment of coactivators. After this exchange of coregulators, RNA polymerase II is recruited and mRNA transcription is initiated. Most NRs bind to their DNA response elements in a sequence-specific manner as dimers, functioning either as homodimers or as heterodimers with the RXR. RA: retinoic acid. Modified from [13, 94].](https://figures.cochat.ai/paper-figures/361837cf3501426ab4e2d45d6534adec/nuclear-receptors-in-nonalcoholic-fatty-liver-disease-figure-1.jpg)


Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“While their role in cholesterol metabolism and hepatic steatosis is known quite well, they may also be involved in the regulation of hepatic inflammation and fibrosis.[157]”
From Nuclear receptors in liver fibrosis (2021) · cites this paper as [157]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The nuclear receptor superfamily: the second decade
Mangelsdorf, D. J., Thummel, C., Beato, M., Herrlich, P., Schütz, G., Umesono, K., Blumberg, B., Kastner, P., Mark, M., Chambon, P., et al. (1995) · Cell · doi:10.1016/0092-8674(95)90199-x · Cited by 6,964
SREBPs: activators of the complete program of cholesterol and fatty acid synthesis in the liver
Horton, J. D., Goldstein, J. L., & Brown, M. S. (2002) · Journal of Clinical Investigation · doi:10.1172/jci15593 · Cited by 4,794
The peroxisome proliferator-activated receptor-γ is a negative regulator of macrophage activation
Ricote, M., Li, A. C., Willson, T. M., Kelly, C. J., & Glass, C. K. (1998) · Nature · doi:10.1038/34178 · Cited by 3,525
Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity.
MATTEONI, C., YOUNOSSI, Z., GRAMLICH, T., BOPARAI, N., LIU, Y., & MCCULLOUGH, A. (1999) · Gastroenterology · doi:10.1016/s0016-5085(99)70506-8 · Cited by 3,345
The RXR heterodimers and orphan receptors
Mangelsdorf, D. J., & Evans, R. M. (1995) · Cell · doi:10.1016/0092-8674(95)90200-7 · Cited by 3,158
Identification of a nuclear receptor for bile acids
Makishima, M., Okamoto, A. Y., Repa, J. J., Tu, H., Learned, R. M., Luk, A., Hull, M. V., Lustig, K. D., Mangelsdorf, D. J., & Shan, B. (1999) · Science · doi:10.1126/science.284.5418.1362 · Cited by 2,714
Nonalcoholic Fatty Liver Disease: From Steatosis to Cirrhosis
Farrell, G. C., & Larter, C. Z. (2006) · Hepatology · doi:10.1002/hep.20973 · Cited by 2,414
Bile Acids: Natural Ligands for an Orphan Nuclear Receptor
Parks, D. J., Blanchard, S. G., Bledsoe, R. K., Chandra, G., Consler, T. G., Kliewer, S. A., Stimmel, J. B., Willson, T. M., Zavacki, A. M., Moore, D. D., et al. (1999) · Science · doi:10.1126/science.284.5418.1365 · Cited by 2,274
The coregulator exchange in transcriptional functions of nuclear receptors
Glass, C. K., & Rosenfeld, M. G. (2000) · Genes & Development · doi:10.1101/gad.14.2.121 · Cited by 2,233 · cited 1×
“Binding of a ligand to LXR causes a conformational change that facilitates inactivation of the corepressor complex and the transcription of target genes [27].”
BackgroundInflammation: the link between insulin resistance, obesity and diabetes
Dandona, P. (2004) · Trends in Immunology · doi:10.1016/j.it.2003.10.013 · Cited by 2,170 · cited 1×
“Several recent studies have shown that a family of transcription factors, named the peroxisome-proliferator-activated receptors (PPARs), improve several of the metabolic abnormalities associated with insulin resistance and impaired fat metabolism [40].”
BackgroundA transcriptional co-repressor that interacts with nuclear hormone receptors
Chen, J. D., & Evans, R. M. (1995) · Nature · doi:10.1038/377454a0 · Cited by 1,763
Repa, J. J., Liang, G., Ou, J., Bashmakov, Y., Lobaccaro, J.-M. A., Shimomura, I., Shan, B., Brown, M. S., Goldstein, J. L., & Mangelsdorf, D. J. (2000) · Genes & Development · doi:10.1101/gad.844900 · Cited by 1,692
Peroxisome proliferator–activated receptor α mediates the adaptive response to fasting
Kersten, S., Seydoux, J., Peters, J. M., Gonzalez, F. J., Desvergne, B., & Wahli, W. (1999) · Journal of Clinical Investigation · doi:10.1172/jci6223 · Cited by 1,649
Molecular Basis for Feedback Regulation of Bile Acid Synthesis by Nuclear Receptors
Lu, T. T., Makishima, M., Repa, J. J., Schoonjans, K., Kerr, T. A., Auwerx, J., & Mangelsdorf, D. J. (2000) · Molecular Cell · doi:10.1016/s1097-2765(00)00050-2 · Cited by 1,487
Regulation of Absorption and ABC1-Mediated Efflux of Cholesterol by RXR Heterodimers
Repa, J. J., Turley, S. D., Lobaccaro, J.-M. A., Medina, J., Li, L., Lustig, K., Shan, B., Heyman, R. A., Dietschy, J. M., & Mangelsdorf, D. J. (2000) · Science · doi:10.1126/science.289.5484.1524 · Cited by 1,301
Principles for modulation of the nuclear receptor superfamily
Gronemeyer, H., Gustafsson, J.-Å., & Laudet, V. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1551 · Cited by 1,226
Identification of a nuclear receptor that is activated by farnesol metabolites
Forman, B. M., Goode, E., Chen, J., Oro, A. E., Bradley, D. J., Perlmann, T., Noonan, D. J., Burka, L. T., McMorris, T., Lamph, W. W., et al. (1995) · Cell · doi:10.1016/0092-8674(95)90530-8 · Cited by 1,210
A unified nomenclature system for the nuclear receptor superfamily
(1999) · Cell · doi:10.1016/s0092-8674(00)80726-6 · Cited by 1,208 · cited 1×
“PPARβ/δ is expressed ubiquitously, but its levels may vary considerably [42, 43].”
BackgroundReciprocal regulation of inflammation and lipid metabolism by liver X receptors
Joseph, S. B., Castrillo, A., Laffitte, B. A., Mangelsdorf, D. J., & Tontonoz, P. (2003) · Nature Medicine · doi:10.1038/nm820 · Cited by 1,158
LXR, a nuclear receptor that defines a distinct retinoid response pathway.
Willy, P. J., Umesono, K., Ong, E. S., Evans, R. M., Heyman, R. A., & Mangelsdorf, D. J. (1995) · Genes & Development · doi:10.1101/gad.9.9.1033 · Cited by 1,123
New Insights Into the Regulation of HDL Metabolism and Reverse Cholesterol Transport
Lewis, G. F., & Rader, D. J. (2005) · Circulation Research · doi:10.1161/01.res.0000170946.56981.5c · Cited by 1,093
Oliver, W. R., Shenk, J. L., Snaith, M. R., Russell, C. S., Plunket, K. D., Bodkin, N. L., Lewis, M. C., Winegar, D. A., Sznaidman, M. L., Lambert, M. H., et al. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.091021198 · Cited by 1,046
The Nuclear Pregnane X Receptor: A Key Regulator of Xenobiotic Metabolism
Kliewer, S. A., Goodwin, B., & Willson, T. M. (2002) · Endocrine Reviews · doi:10.1210/er.2001-0038 · Cited by 921
PPAR and human metabolic disease
Semple, R. K. (2006) · Journal of Clinical Investigation · doi:10.1172/jci28003 · Cited by 827
Moore, L. B., Parks, D. J., Jones, S. A., Bledsoe, R. K., Consler, T. G., Stimmel, J. B., Goodwin, B., Liddle, C., Blanchard, S. G., Willson, T. M., et al. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.m001215200 · Cited by 815
Joseph, S. B., Laffitte, B. A., Patel, P. H., Watson, M. A., Matsukuma, K. E., Walczak, R., Collins, J. L., Osborne, T. F., & Tontonoz, P. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m111041200 · Cited by 779
PPARs: therapeutic targets for metabolic disease
Berger, J. P., Akiyama, T. E., & Meinke, P. T. (2005) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2005.03.003 · Cited by 713
Overproduction of large VLDL particles is driven by increased liver fat content in man
Adiels, M., Taskinen, M.-R., Packard, C., Caslake, M. J., Soro-Paavonen, A., Westerbacka, J., Vehkavaara, S., Häkkinen, A., Olofsson, S.-O., Yki-Järvinen, H., et al. (2006) · Diabetologia · doi:10.1007/s00125-005-0125-z · Cited by 690
LXRs control lipid-inducible expression of the apolipoprotein E gene in macrophages and adipocytes
Laffitte, B. A., Repa, J. J., Joseph, S. B., Wilpitz, D. C., Kast, H. R., Mangelsdorf, D. J., & Tontonoz, P. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.98.2.507 · Cited by 683
An overview on biological mechanisms of PPARs
KOTA, B., HUANG, T., & ROUFOGALIS, B. (2005) · Pharmacological Research · doi:10.1016/j.phrs.2004.07.012 · Cited by 666
Nakae, J., Kitamura, T., Silver, D. L., & Accili, D. (2001) · Journal of Clinical Investigation · doi:10.1172/jci12876 · Cited by 652
Nakae, J., Kitamura, T., Silver, D. L., & Accili, D. (2001) · Journal of Clinical Investigation · doi:10.1172/jci200112876 · Cited by 652
PPAR : a dagger in the heart of the metabolic syndrome
Barish, G. D. (2006) · Journal of Clinical Investigation · doi:10.1172/jci27955 · Cited by 641 · cited 1×
“PPARβ/δ regulates glucose utilization and lipoprotein metabolism by promoting reverse cholesterol transport [57–60].”
BackgroundYu, S., Matsusue, K., Kashireddy, P., Cao, W.-Q., Yeldandi, V., Yeldandi, A. V., Rao, M. S., Gonzalez, F. J., & Reddy, J. K. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m210062200 · Cited by 619
LXRS AND FXR: The Yin and Yang of Cholesterol and Fat Metabolism
Kalaany, N. Y., & Mangelsdorf, D. J. (2006) · Annual Review of Physiology · doi:10.1146/annurev.physiol.68.033104.152158 · Cited by 615
NATURE OF THE HEPATOMEGALIC EFFECT PRODUCED BY ETHYL-CHLOROPHENOXY-ISOBUTYRATE IN THE RAT
HESS, R., STÄUBLI, W., & RIESS, W. (1965) · Nature · doi:10.1038/208856a0 · Cited by 594
The nuclear receptor superfamily
Robinson-Rechavi, M., Garcia, H. E., & Laudet, V. (2003) · Journal of Cell Science · doi:10.1242/jcs.00247 · Cited by 587
The Farnesoid X Receptor Modulates Adiposity and Peripheral Insulin Sensitivity in Mice
Cariou, B., van Harmelen, K., Duran-Sandoval, D., van Dijk, T. H., Grefhorst, A., Abdelkarim, M., Caron, S., Torpier, G., Fruchart, J.-C., Gonzalez, F. J., et al. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m510258200 · Cited by 552
Reciprocal activation of Xenobiotic response genes by nuclear receptors SXR/PXR and CAR
Xie, W., Barwick, J. L., Simon, C. M., Pierce, A. M., Safe, S., Blumberg, B., Guzelian, P. S., & Evans, R. M. (2000) · Genes & Development · doi:10.1101/gad.846800 · Cited by 508
Pineda Torra, I., Claudel, T., Duval, C., Kosykh, V., Fruchart, J.-C., & Staels, B. (2003) · Molecular Endocrinology · doi:10.1210/me.2002-0120 · Cited by 487
SREBPs: activators of the complete program of cholesterol and fatty acid synthesis in the liver
Horton, J. D., Goldstein, J. L., & Brown, M. S. (2002) · Journal of Clinical Investigation · doi:10.1172/jci200215593 · Cited by 480
The Liver X Receptor (LXR) and Hepatic Lipogenesis
Cha, J.-Y., & Repa, J. J. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m605023200 · Cited by 470
Hashimoto, T., Cook, W. S., Qi, C., Yeldandi, A. V., Reddy, J. K., & Rao, M. S. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.m910350199 · Cited by 444
Seol, W. (1995) · Molecular Endocrinology · doi:10.1210/me.9.1.72 · Cited by 393
The Farnesoid X-receptor Is an Essential Regulator of Cholesterol Homeostasis
Lambert, G., Amar, M. J. A., Guo, G., Brewer, H. B., Gonzalez, F. J., & Sinal, C. J. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m209525200 · Cited by 392
BAREing it all: the adoption of LXR and FXR and their roles in lipid homeostasis
Edwards, P. A., Kast, H. R., & Anisfeld, A. M. (2002) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)30180-2 · Cited by 385
Chiang, J. Y. L., Kimmel, R., & Stroup, D. (2001) · Gene · doi:10.1016/s0378-1119(00)00518-7 · Cited by 375
Zhou, J., Zhai, Y., Mu, Y., Gong, H., Uppal, H., Toma, D., Ren, S., Evans, R. M., & Xie, W. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m511116200 · Cited by 368
Zhang, Y., Castellani, L. W., Sinal, C. J., Gonzalez, F. J., & Edwards, P. A. (2004) · Genes & Development · doi:10.1101/gad.1138104 · Cited by 368
Schuler, M., Ali, F., Chambon, C., Duteil, D., Bornert, J.-M., Tardivel, A., Desvergne, B., Wahli, W., Chambon, P., & Metzger, D. (2006) · Cell Metabolism · doi:10.1016/j.cmet.2006.10.003 · Cited by 367
Orphan Nuclear Receptors as eLiXiRs and FiXeRs of Sterol Metabolism
Lu, T. T., Repa, J. J., & Mangelsdorf, D. J. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.r100035200 · Cited by 357
Sterol upregulation of human CETP expression in vitro and in transgenic mice by an LXR element
Luo, Y., & Tall, A. R. (2000) · Journal of Clinical Investigation · doi:10.1172/jci8573 · Cited by 351
FXR, a multipurpose nuclear receptor
Lee, F. Y., Lee, H., Hubbert, M. L., Edwards, P. A., & Zhang, Y. (2006) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2006.08.002 · Cited by 344
The Expanding Cosmos of Nuclear Receptor Coactivators
Lonard, D. M., & O'Malley, B. W. (2006) · Cell · doi:10.1016/j.cell.2006.04.021 · Cited by 317
Nuclear Receptor Coregulators and Human Disease
Lonard, D. M., Lanz, R. B., & O’Malley, B. W. (2007) · Endocrine Reviews · doi:10.1210/er.2007-0012 · Cited by 302
Zhang, Y., Kast-Woelbern, H. R., & Edwards, P. A. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m209505200 · Cited by 286
Regulation of Lipoprotein Lipase by the Oxysterol Receptors, LXRα and LXRβ
Zhang, Y., Repa, J. J., Gauthier, K., & Mangelsdorf, D. J. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m107823200 · Cited by 284
Nuclear Receptors in Liver Disease Δ
Wagner, M., Zollner, G., & Trauner, M. (2011) · Hepatology · doi:10.1002/hep.24148 · Cited by 260 · cited 1×
“NRs control fatty acid transport from peripheral adipose tissue to the liver and regulate several critical metabolic steps involved in the pathogenesis of NAFLD, including fat storage, export, uptake, oxidation, and lipolysis [94].”
BackgroundNuclear receptors in macrophage biology: at the crossroads of lipid metabolism and inflammation
Castrillo, A., & Tontonoz, P. (2004) · Annual Review of Cell and Developmental Biology · doi:10.1146/annurev.cellbio.20.012103.134432 · Cited by 260
Wei, P., Zhang, J., Dowhan, D. H., Han, Y., & Moore, D. D. (2002) · The Pharmacogenomics Journal · doi:10.1038/sj.tpj.6500087 · Cited by 240
Latruffe, N., & Vamecq, J. (1997) · Biochimie · doi:10.1016/s0300-9084(97)81496-4 · Cited by 237
Transcriptional control by nuclear receptors
Beato, M. (1991) · The FASEB Journal · doi:10.1096/fasebj.5.7.2010057 · Cited by 225
Transcription coactivators for peroxisome proliferator-activated receptors
YU, S., & REDDY, J. (2007) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2007.01.008 · Cited by 222
Moreau, A., Vilarem, M. J., Maurel, P., & Pascussi, J. M. (2008) · Molecular Pharmaceutics · doi:10.1021/mp700103m · Cited by 220
Peroxisome Proliferator-Activated Receptors, Coactivators, and Downstream Targets
Qi, C., Zhu, Y., & Reddy, J. K. (2000) · Cell Biochemistry and Biophysics · doi:10.1385/cbb:32:1-3:187 · Cited by 216
PPAR gamma and human metabolic disease
Chatterjee, K. (2006) · 8th European Congress of Endocrinology incorporating the British Endocrine Societies · Cited by 209
Zingarelli, B., Sheehan, M., Hake, P. W., O’Connor, M., Denenberg, A., & Cook, J. A. (2003) · The Journal of Immunology · doi:10.4049/jimmunol.171.12.6827 · Cited by 199
Peroxisomal β-Oxidation and Steatohepatitis
Rao, M. S., & Reddy, J. K. (2001) · Seminars in Liver Disease · doi:10.1055/s-2001-12928 · Cited by 193
Current concepts in the pathogenesis of nonalcoholic fatty liver disease
Méndez‐Sánchez, N., Arrese, M., Zamora‐Valdés, D., & Uribe, M. (2007) · Liver International · doi:10.1111/j.1478-3231.2007.01483.x · Cited by 184
Self-citationHansen, J. B., Zhang, H., Rasmussen, T. H., Petersen, R. K., Flindt, E. N., & Kristiansen, K. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m005567200 · Cited by 173
Nuclear receptor regulation of hepatic function
Karpen, S. J. (2002) · Journal of Hepatology · doi:10.1016/s0168-8278(02)00129-0 · Cited by 170
Repression of Farnesoid X Receptor during the Acute Phase Response
Kim, M. S., Shigenaga, J. K., Moser, A., Feingold, K. R., & Grünfeld, C. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m212633200 · Cited by 166
Role of the Constitutive Androstane Receptor in Xenobiotic-Induced Thyroid Hormone Metabolism
Qatanani, M., Zhang, J., & Moore, D. D. (2005) · Endocrinology · doi:10.1210/en.2004-1350 · Cited by 166
The pregnane X receptor: from bench to bedside
Ma, X., Idle, J. R., & Gonzalez, F. J. (2008) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.4.7.895 · Cited by 161
Roth, A. B., Looser, R., Kaufmann, M., Blättler, S. M., Rencurel, F., Huang, W., Moore, D. D., & Meyer, U. (2008) · Molecular Pharmacology · doi:10.1124/mol.107.041012 · Cited by 161
The Roles of Nuclear Receptors CAR and PXR in Hepatic Energy Metabolism
Konno, Y., Negishi, M., & Kodama, S. (2008) · Drug Metabolism and Pharmacokinetics · doi:10.2133/dmpk.23.8 · Cited by 146
Trends in liver disease prevalence in Mexico from 2005 to 2050 through mortality data
Méndez‐Sánchez, N., Villa, A. R., Chávez-Tapia, N. C., Ponciano‐Rodríguez, G., Almeda‐Valdés, P., González, D., & Uribe, M. (2005) · Annals of Hepatology · doi:10.1016/s1665-2681(19)32086-1 · Cited by 141
Self-citationAngiopoietin-like Protein 3 Mediates Hypertriglyceridemia Induced by the Liver X Receptor
Inaba, T., Matsuda, M., Shimamura, M., Takei, N., Terasaka, N., Ando, Y., Yasumo, H., Koishi, R., Makishima, M., & Shimomura, I. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m213202200 · Cited by 140
Maglich, J. M., Lobe, D. C., & Moore, J. T. (2008) · Journal of Lipid Research · doi:10.1194/jlr.m800226-jlr200 · Cited by 126
The farnesoid X receptor induces very low density lipoprotein receptor gene expression
Sirvent, A., Claudel, T., Martin, G., Brozek, J., Kosykh, V., Darteil, R., Hum, D. W., Fruchart, J., & Staels, B. (2004) · FEBS Letters · doi:10.1016/j.febslet.2004.04.026 · Cited by 122
Functional and structural comparison of PXR and CAR
Moore, J. T., Moore, L. B., Maglich, J. M., & Kliewer, S. A. (2003) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/s0304-4165(02)00481-6 · Cited by 119
Insulin Regulation of PEPCK Gene Expression: A Model for Rapid and Reversible Modulation
Quinn, P. G., & Yeagley, D. (2005) · Current Drug Targets - Immune, Endocrine & Metabolic Disorders · doi:10.2174/156800805774912962 · Cited by 113
Yamazaki, Y., Kakizaki, S., Horiguchi, N., Sohara, N., Sato, K., Takagi, H., Mori, M., & Negishi, M. (2006) · Gut · doi:10.1136/gut.2006.093260 · Cited by 95
Jakel, H., Nowak, M., Moitrot, E., Dehondt, H., Hum, D. W., Pennacchio, L. A., Fruchart-Najib, J., & Fruchart, J.-C. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m404744200 · Cited by 93
Direct Regulatory Effect of Fatty Acids on Macrophage Lipoprotein Lipase
Michaud, S. E., & Renier, G. (2001) · Diabetes · doi:10.2337/diabetes.50.3.660 · Cited by 91
Martin, G., Poirier, H., Crombie, D. L., Fruchart, J., Heyman, R. A., Besnard, P., Auwerx, J. H., & Hennuyer, N. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.275.17.12612 · Cited by 87
New Insights on the Xenobiotic-Sensing Nuclear Receptors in Liver Diseases – CAR and PXR-
Kakizaki, S., Yamazaki, Y., Takizawa, D., & Negishi, M. (2008) · Current Drug Metabolism · doi:10.2174/138920008785821666 · Cited by 83
PXR and LXR in Hepatic Steatosis: A New Dog and an Old Dog with New Tricks
Lee, J. H., Zhou, J., & Xie, W. (2008) · Molecular Pharmaceutics · doi:10.1021/mp700121u · Cited by 72
Fourcade, S., Savary, S., Albet, S., Gauthé, D., Gondcaille, C., Pineau, T., Bellenger, J., Bentejac, M., Holzinger, A., Berger, J., et al. (2001) · European Journal of Biochemistry · doi:10.1046/j.1432-1327.2001.02249.x · Cited by 70
Kassam, A., Winrow, C. J., Fernandez-Rachubinski, F., Capone, J. P., & Rachubinski, R. A. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.275.6.4345 · Cited by 61
Arrese, M., & Karpen, S. J. (2010) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2010.2 · Cited by 54
Méndez‐Sánchez, N., García-Villegas, E. A., Merino-Zeferino, B., Ochoa-Cruz, S., Villa, A. R., Madrigal, H., Kobashi-Margáin, R. A., Gutiérrez-Grobe, Y., Chávez-Tapia, N. C., Ponciano‐Rodríguez, G., et al. (2010) · Annals of Hepatology · doi:10.1016/s1665-2681(19)31619-9 · Cited by 38
Self-citationLee, C., & Wei, L. (1999) · Biochemistry · doi:10.1021/bi9903547 · Cited by 26
Méndez‐Sánchez, N., Chávez-Tapia, N. C., Zamora‐Valdés, D., et al. (2006) · Mini-Reviews in Medicinal Chemistry · doi:10.2174/138955706777435689 · Cited by 26
Self-citationRole of nonalcoholic fatty liver disease in hepatocellular carcinoma
Chávez-Tapia, N. C., Méndez‐Sánchez, N., & Uribe, M. (2009) · Annals of Hepatology · doi:10.1016/s1665-2681(19)31824-1 · Cited by 22
Self-citationPhenobarbital induction of cytochrome p-450 b,e genes is dependent on protein synthesis
Chianale, J., Mulholland, L. T., Traber, P. G., et al. (1988) · Hepatology · doi:10.1002/hep.1840080223 · Cited by 18
[Obesity and non-alcoholic steatohepatitis].
Méndez‐Sánchez, N., Chávez-Tapia, N. C., & Uribe, M. (2005) · PubMed · Cited by 8
Self-citation
Research works printed but not linked: 3
- 2004, Gaceta Medica de Mexico, 140, S67
- 10.1073/pnas.021488798 · doi:10.1073/pnas.021488798 · Paper page
- 1995, Molecular Endocrinology, 9, 72
Cited by
Circadian Homeostasis of Liver Metabolism Suppresses Hepatocarcinogenesis
Kettner, N. M., Voicu, H., Finegold, M. J., Coarfa, C., Sreekumar, A., Putluri, N., Katchy, C. A., Lee, C., Moore, D. D., & Fu, L. (2016) · Cancer Cell · doi:10.1016/j.ccell.2016.10.007 · Cited by 508
“FXR also plays a broad role in liver function by inhibiting steatosis and inflammatory genes (Lopez-Velazquez et al., 2012).”
BackgroundFXR signaling in the enterohepatic system
Matsubara, T., Li, F., & Gonzalez, F. J. (2013) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2012.05.004 · Cited by 381
Nuclear receptors and nonalcoholic fatty liver disease
Cave, M. C., Clair, H. B., Hardesty, J. E., Falkner, K. C., Feng, W., Clark, B. J., Sidey, J., Shi, H., Aqel, B. A., McClain, C. J., et al. (2016) · Biochimica et Biophysica Acta (BBA) - Gene Regulatory Mechanisms · doi:10.1016/j.bbagrm.2016.03.002 · Cited by 279
Nuclear receptors in liver fibrosis
Königshofer, P., Brusilovskaya, K., Petrenko, O., Hofer, B. S., Schwabl, P., Trauner, M., & Reiberger, T. (2021) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2021.166235 · Cited by 45
Metadata
- Authors
- López-Velázquez, J. A., Carrillo-Córdova, L. D., Chávez-Tapia, N. C., Uribe, M., & Méndez-Sánchez, N.
- Affiliations
- Liver Research Unit, Medica Sur Clinic & Foundation, Puente de Piedra 150, Colonia Toriello Guerra, 14050 Tlalpan, Mexico City, Mexico
- Hospital Médica Sur (MX)
- Venue
- Journal of Lipids
- Publisher
- Wiley
- Published
- 2012
- Volume
- 2012
- Pages
- 1-10
- ISSN
- 2090-3030 (ISSN-L)
- 2090-3049
- PMC
- PMC3236492
- OpenAlex
- W2082815388
- Cited by
- 48
- References
- 97
- Citations by year
- 2026: 1 · 2025: 5 · 2024: 1 · 2023: 5 · 2021: 4 · 2020: 5 · 2019: 3 · 2018: 2 · 2017: 6 · 2016: 5 · 2015: 2 · 2014: 3 · 2013: 5 · 2012: 1
- FWCI
- 2.17
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Locations
- Journal of Lipids (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- Consejo Nacional de Ciencia y Tecnología (62460)
- Medica Sur Clinic & Foundation (62460)
- Topics
- Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Cholesterol and Lipid Metabolism
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Peroxisome Proliferator-Activated Receptors
- Keywords
- nuclear receptors, non-alcoholic fatty liver disease, hepatic lipid metabolism, hepatic glucose metabolism, bile acid homeostasis, drug detoxification, liver fibrosis, liver regeneration, inflammation, oxysterols, fatty acids, transcriptional regulation, therapeutic target
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.